Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis
Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
Authors
- Thomas Corbridge
- Wendy C. Moore (ORCID: https://orcid.org/0000-0001-6869-3059)
- Alexandra Stach-Klysh (ORCID: https://orcid.org/0000-0003-3465-7943)
- Arijita Deb (ORCID: https://orcid.org/0000-0002-4570-0364)
- Elizabeth Packnett (ORCID: https://orcid.org/0000-0002-4731-6956)
- Megan Richards (ORCID: https://orcid.org/0000-0003-0737-389X)
- Donna McMorrow
Institutions
- Providence College (US)
- Merit Network (US)
- Pulmonary and Allergy Associates (US)
- Durham VA Medical Center (US)
- Ann Arbor Center for Independent Living (US)
- Wake Forest University (US)
Publication Details
- Journal
- Journal of Asthma
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/02770903.2025.2450640
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33